Is Preventive Migraine Treatment Different From Acute Relief? What Each Part of the Plan Does

She keeps two very different things in the same kitchen drawer. One is the tablet she reaches for the moment the familiar throb starts behind her right eye. The other is the one she takes every evening whether her head hurts or not, and on good weeks she quietly wonders why she bothers. When her neurologist asked how each was going, she realized she had been grading them against the same standard: does the pain stop today?

That is the most common confusion in the acute vs preventive migraine treatment conversation, and it is an understandable one. Both are called migraine medicine. Both come from the same pharmacy. Yet they are built to answer different questions on different timelines.

This explainer walks through what each part of a migraine plan is trying to do, how the main medicine classes work, who is usually offered prevention and who is asked to wait, and how to tell whether a plan is working without expecting the wrong thing from the wrong drawer.

Acute vs preventive migraine treatment: two jobs, not two versions of one job

Think of a house in a region prone to storms. Acute treatment is the mop, the bucket and the tarp you grab when water is already coming through the ceiling. Preventive treatment is the roof repair you schedule in dry weather so fewer storms get in at all. Nobody expects a mop to keep the roof from leaking, and nobody expects a new roof to dry the carpet that is already soaked.

Acute migraine treatment, sometimes called abortive or rescue treatment, is taken when an attack begins. Its goals are narrow and short-term: relieve head pain, calm nausea and light sensitivity, and return you to normal function within a few hours. It is judged attack by attack.

Preventive treatment, also called prophylaxis, is taken on a fixed schedule regardless of whether you have a headache that day. It works upstream, lowering the brain’s readiness to launch an attack. Its goals are measured over months: fewer migraine days, shorter attacks, milder attacks, and a better response when you do need rescue medicine. The Mayo Clinic describes prevention as an option when attacks are frequent, long-lasting or severe, or when acute treatments are not helping enough.

The two categories also differ in how you experience them. Acute medicine gives fast feedback; you know within hours whether it helped. Preventive medicine gives slow, statistical feedback that only shows up when you compare this month’s headache diary with the one from before you started. That gap in feedback is why so many people abandon prevention early, and why clinicians ask for patience before judging it.

A well-built plan almost always contains both parts. Even people whose prevention works very well keep an acute option for the attacks that still get through. The rest of this article looks at each part in turn.

What actually happens during a migraine attack, and where each treatment steps in

Migraine is not simply a bad headache. According to the National Institute of Neurological Disorders and Stroke, it is a neurological condition in which the brain’s pain-processing networks become abnormally excitable, and a single attack can last anywhere from 4 to 72 hours if untreated. Understanding the sequence explains why timing matters so much for acute drugs and why preventives are aimed at a different target altogether.

Many attacks unfold in phases. A prodrome, meaning a set of early changes such as mood shifts, yawning or neck stiffness, can begin hours or a day before pain. Some people then have an aura, which is a set of temporary neurological symptoms such as flickering lights or numbness that usually resolve within an hour. The headache phase follows, driven in part by activation of the trigeminal nerve, the main sensory nerve of the face and head, and the release of chemical messengers around blood vessels in the meninges, the brain’s protective lining. One of the most studied messengers is calcitonin gene-related peptide, usually shortened to CGRP, a small protein that widens blood vessels and amplifies pain signaling.

Acute treatments intervene once this cascade is under way. They try to interrupt pain signaling, reduce inflammation, or block CGRP’s effects before the attack becomes fully established, which is why guidance from the NHS and others emphasizes taking acute medicine early rather than waiting to see whether the pain becomes severe.

Preventive treatments do not wait for the cascade. Taken continuously, they aim to raise the threshold that has to be crossed before an attack begins, by dampening neuronal excitability, blocking CGRP over the long term, or altering the way pain circuits respond to triggers. The attack that never starts is prevention’s whole point, and it is why a good preventive can look like nothing is happening.

How do triptans and other acute migraine medicines work?

Acute options fall into a handful of classes, each with a distinct mechanism. Which one suits a given person depends on attack pattern, other health conditions and side effects, and that judgment sits with the prescribing clinician.

Simple pain relievers come first for many people. Nonsteroidal anti-inflammatory drugs, a class that reduces inflammation-related pain signaling, and acetaminophen are widely used for milder attacks. The NHS notes they tend to work best when taken at the first sign of an attack rather than once pain has peaked.

Triptans are migraine-specific medicines that act on serotonin receptors. In plain terms, they narrow swollen blood vessels around the brain and quiet the trigeminal nerve’s pain messaging. Because of that vessel-narrowing action, the Mayo Clinic notes they are generally avoided in people at risk of stroke or heart attack, which is one reason a full cardiovascular history matters before one is prescribed. Several formulations exist, including tablets, nasal sprays and injections, so that people who vomit early in an attack still have an option.

Gepants are a newer class that block the CGRP receptor directly, without constricting blood vessels. Ditans are another newer class that act on a different serotonin receptor subtype and also avoid vessel constriction. Both were developed partly for people who cannot take triptans.

Anti-nausea medicines, sometimes called antiemetics, are often paired with a pain reliever because migraine slows stomach emptying and nausea itself is disabling. Ergot derivatives are an older class occasionally used for prolonged attacks.

Common threads run through all of them. Early use generally beats late use. Formulation matters when nausea is prominent. And every acute class carries a ceiling on how many days a month it can safely be used, which leads directly to the problem of medication overuse headache discussed later.

Acute vs preventive migraine treatment at a glance

Laying the two approaches side by side makes the distinction easier to hold on to when you are in a clinic room with a lot of new vocabulary in the air. The rows below summarize mainstream guidance from the Mayo Clinic, Cleveland Clinic and NHS.

Feature	Acute (rescue) treatment	Preventive (prophylactic) treatment
When it is taken	At the start of an attack	On a regular schedule, attack or not
Main goal	Stop pain and nausea within hours	Fewer, shorter, milder attacks over months
How success is judged	Attack by attack	By comparing headache diary months
Time to know if it helps	Usually within a few hours	Typically several weeks to a few months (Mayo Clinic)
Typical classes	NSAIDs, acetaminophen, triptans, gepants, ditans, antiemetics	Blood pressure medicines, antiseizure medicines, certain antidepressants, CGRP antibodies, some gepants, botulinum toxin for chronic migraine
Main risk of overuse	Medication overuse headache	Class-specific side effects; not overuse headache
Who usually needs it	Nearly everyone with migraine	People with frequent, severe or poorly controlled attacks

Two rows deserve a second look. The time-to-know row explains most of the frustration people feel: acute drugs earn or lose trust within an afternoon, while preventives ask for months before a fair verdict. The overuse row explains a paradox that surprises many patients, namely that using the fast-acting drawer too often can make the underlying condition worse, whereas the daily preventive, when taken as prescribed, does not carry that particular risk.

Neither column is better. They are answers to different questions, and the table is a map rather than a menu; the actual choice within each column is a clinical decision made with your care team.

What are the migraine preventive medication options?

The preventive shelf looks odd at first glance because so many of its medicines were originally developed for something else. That history reflects how migraine research unfolded: clinicians noticed fewer headaches in patients taking certain drugs for other reasons, and trials followed. The Mayo Clinic and Cleveland Clinic group the main options as follows.

• Blood pressure lowering medicines, particularly beta blockers and some calcium channel blockers, are among the longest-used preventives. They appear to steady the excitability of pain networks rather than working through blood pressure itself.
• Antiseizure medicines calm overactive nerve firing. Their side effect profiles differ substantially, which matters for people planning pregnancy or with kidney, weight or mood concerns.
• Certain antidepressants, especially tricyclic agents, alter serotonin and other messenger levels involved in pain processing. They may be considered regardless of whether depression is present, and can help when sleep disturbance travels with migraine.
• CGRP monoclonal antibodies are laboratory-made proteins that bind either CGRP itself or its receptor, blocking the messenger for extended periods. They are given by injection at spaced intervals and were the first class designed specifically for migraine prevention.
• Some gepants, the oral CGRP-receptor blockers described earlier, are also used preventively when taken on a regular schedule rather than only during attacks.
• Botulinum toxin injections around the head and neck are used for chronic migraine, which the Mayo Clinic defines as headache on 15 or more days a month for more than 3 months, with migraine features on at least 8 of those days.

No option is universally first. Guidance emphasizes matching the class to the individual: coexisting conditions, other medicines, pregnancy plans, tolerability and personal priorities all weigh in. A person with high blood pressure and migraine may be steered one way; someone with low blood pressure and fatigue another. The prescriber, not the list, makes that call.

When to start migraine prevention, and who is usually asked to wait

The most searched question about prevention is essentially a threshold question: how bad does it have to get? Mainstream guidance answers with a combination of frequency, disability and response to acute treatment rather than a single number.

Frequency is the starting point. The Cleveland Clinic notes that preventive treatment is often considered when someone has four or more migraine days a month, and the Mayo Clinic lists frequent, long-lasting or severe attacks as reasons to discuss it. Frequency alone can understate the picture, though. Two attacks a month that each cost three days in bed is a heavier burden than six brief ones that respond to a single tablet.

Response to acute treatment is the second consideration. When rescue medicines fail regularly, cause troublesome side effects, or cannot be used because of heart or stroke risk, prevention becomes more attractive even at lower frequencies.

The third trigger is overuse risk. Someone who finds themselves reaching for acute medicine on many days a month is drifting toward medication overuse headache, and prevention is one of the tools used to pull back from that edge.

Who is usually asked to wait? People with infrequent attacks that respond well to early acute treatment generally do not need a daily medicine and its side effects. Prevention is also often deferred, or the choice of agent is changed, in pregnancy and while trying to conceive, because several classic preventives are not suitable then; this is a conversation to have before conception where possible. Some clinicians also want a few months of diary data first, so the baseline is clear enough to judge the preventive against.

None of these are rules that a patient applies alone. They are the questions a clinician weighs, and the honest answer to when to start is: when the burden, the diary and the risks together say the roof needs fixing.

Why the same medicine can be a rescue drug or a preventive

Here is where the neat two-drawer picture gets a little more interesting. A few medicines, notably certain gepants, appear in both columns of the table above. How can one molecule be both a mop and a roof repair?

The answer lies in schedule rather than substance. When a CGRP-receptor blocker is taken at the start of an attack, it interrupts the CGRP signaling that is already amplifying pain, functioning as acute treatment. When the same class is taken on a regular schedule, it keeps CGRP activity suppressed continuously, lowering the brain’s readiness to begin an attack, which is prevention. The mechanism is identical; the goal and the timing are different.

This dual role has practical consequences that patients notice. A person prescribed a gepant preventively may be told not to double up with the same class for rescue, and to keep a different acute option available. Someone using a gepant only for rescue should not assume it is quietly preventing attacks between uses; it is not, because the drug is not present continuously.

The same logic explains why some older medicines never cross over. Triptans, for example, are effective acute agents but are not used preventively, because their vessel-narrowing action and short duration make continuous use unsuitable, and frequent use pushes toward overuse headache. Beta blockers, at the other end, do nothing useful for an attack already under way; their value is entirely in the steady, background lowering of excitability.

The takeaway for a patient is simple. Ask about each medicine you have been given: is this for the attack, for the background, or, in a few specific cases, for one role only even though the class can do both? Knowing which drawer each belongs in prevents the two most common mistakes, using a preventive to chase pain and using a rescue drug so often it becomes the problem.

What the first weeks and months on a preventive usually look like

Starting prevention rarely feels like a turning point on day one. Understanding the typical arc helps people stay the course long enough to make a fair judgment.

The first days and weeks are often dominated by side effects rather than benefit. Many preventives are started at a low level and increased gradually by the prescriber precisely to soften this period; fatigue, dizziness, changes in appetite, tingling or mood shifts are among the effects reported across the different classes, and which ones appear depends on the medicine. Some settle as the body adjusts; others do not, and that is useful information for the clinician rather than a failure on the patient’s part.

Benefit tends to lag. The Mayo Clinic notes that it can take several weeks to months of consistent use before a preventive’s effect on attack frequency becomes clear. The Cleveland Clinic similarly advises giving a preventive a fair trial of a few months before deciding it has not worked. This is why the headache diary is not optional paperwork; it is the only instrument that can detect a change from, say, eight migraine days a month to five, a difference that is easy to miss by feel and meaningful in real life.

Around the two- to three-month mark, a review typically happens. The prescriber compares the diary with the baseline, weighs side effects against benefit, and decides with the patient whether to continue, adjust or switch. A partial response is common and is not the same as no response; it may be built on rather than abandoned.

Longer term, prevention is not necessarily forever. When attacks have been well controlled for a sustained period, clinicians sometimes discuss a gradual, supervised reduction to see whether the lower frequency holds. That, like every other step, is a decision made with the treating team rather than by stopping on a good week.

What is medication overuse headache, and why does it sit between the two drawers?

Medication overuse headache, sometimes called rebound headache, is a headache that becomes more frequent because acute pain medicine is being taken too often. It is the single most important reason the acute and preventive parts of a plan have to be managed together rather than separately.

The mechanism is not fully understood, but the pattern is well documented. When pain relievers are present in the body most days, the pain-processing system appears to adapt, becoming more sensitive when the medicine wears off. The result is a dull, near-daily headache layered on top of the original migraine, with the rescue drug providing shorter and shorter windows of relief. The Mayo Clinic notes that this can happen with many acute classes, including simple analgesics, combination products containing caffeine, triptans and opioids.

Thresholds matter and are worth knowing. Guidance summarized by the Cleveland Clinic and Mayo Clinic describes risk rising when simple pain relievers are used on 15 or more days a month, or when triptans, ergots, opioids or combination analgesics are used on 10 or more days a month, over a period of months. These numbers describe a risk zone, not a guarantee, and they apply to headache medicines taken for any reason.

The connection to prevention is direct. Someone who has slipped into frequent acute use often cannot simply stop, because withdrawal temporarily worsens headache. Clinicians commonly pair a supervised reduction in acute medicine with the start or adjustment of a preventive, so that as the overused drug is withdrawn, the background frequency of attacks is also falling. The Mayo Clinic notes that headaches often improve after the overused medicine is reduced, though the early weeks can be difficult.

The practical lesson is to count days, not tablets, and to tell the clinician honestly how many days a month rescue medicine is being used. That number, more than almost any other, shapes what the plan should look like.

Are gepants safer than triptans? What the evidence actually shows

People searching this question usually have a specific product in mind, but the honest, useful answer lives at the class level. Gepants and triptans are both effective acute options; they differ in mechanism, in who can take them, and in how much long-term experience exists.

The main safety distinction is cardiovascular. Triptans narrow blood vessels as part of how they work, which is why the Mayo Clinic notes they are generally not recommended for people at risk of stroke or heart attack, and why some people with uncontrolled high blood pressure or certain heart conditions are steered away from them. Gepants block the CGRP receptor without constricting vessels, and they were developed in part to give that group an option. For a person with significant cardiovascular risk, that difference is meaningful. For a healthy adult with no such risk, it is much less of a differentiator.

Overuse is the second distinction. Triptans carry a well-described risk of medication overuse headache at frequent use. Whether gepants carry the same risk is less clear; the evidence base is shorter, and this is an area where clinicians are still gathering experience rather than one where a firm answer exists.

Track record cuts the other way. Triptans have been used in enormous numbers of people over decades, so their side effect profile, including chest tightness, tingling, drowsiness and flushing, is thoroughly mapped. Gepants are newer, and although trials and early real-world use have been reassuring, long-term data are still accumulating. Newer is not automatically safer; it is less studied.

Neither class is universally safer. The right question is safer for whom, and answering it requires the prescriber to weigh heart and stroke risk, attack pattern, other medicines and past responses. If you were told triptans were not suitable for you, that is worth raising when discussing alternatives; if you take a triptan successfully, that is not by itself a reason to change.

What is the most effective preventive treatment for migraine?

The truthful answer disappoints people looking for a winner: there is no single most effective preventive for everyone, and guidance from mainstream sources deliberately avoids crowning one. That is not evasiveness. It reflects what trials show and how migraine varies from one person to the next.

Across the established classes, the average benefit in trials is broadly similar. Preventives are generally judged successful when they cut migraine days by around half, a benchmark that the Cleveland Clinic and others use to describe a meaningful response. Some people achieve far more than that on a given medicine; others achieve nothing on the same one and respond well to a different class. Average results hide this individual variation, which is exactly what matters to the person in the chair.

Selection therefore turns on fit rather than ranking. A preventive that also helps a coexisting condition is often preferred: a beta blocker for someone who also has high blood pressure, a tricyclic for someone whose sleep is poor, an antiseizure agent that is also used for another indication the person has. Conversely, a medicine’s side effect profile may rule it out regardless of its trial data. Weight change, cognitive fog, mood effects and pregnancy safety are frequent deciding factors.

The newer CGRP-targeted options changed the conversation in one specific way. Because they were designed for migraine, they tend to have fewer of the off-target effects that come with borrowing a blood pressure or seizure medicine. Whether that makes them more effective is a separate question; their trial results are in the same broad range as older classes, and access and long-term data considerations mean many clinicians still begin with established options.

What most reliably improves prevention outcomes is not the choice of molecule but the process: a clear baseline diary, a long enough trial, honest reporting of side effects, and willingness to try a second or third class if the first disappoints.

Do non-drug approaches count as prevention?

Yes, and the better guidance treats them as part of the preventive column rather than as an afterthought. They are not a substitute for medication when frequency is high, but for many people they lower the baseline that medication then works on.

Regularity is the theme that runs through the evidence. The migraine brain appears to dislike change, and mainstream sources including the Mayo Clinic and NHS emphasize consistent sleep and wake times, regular meals, steady hydration and routine exercise as measures that reduce attack frequency for some people. Skipped meals and disrupted sleep are among the most commonly reported triggers, which fits the picture of a threshold that is easier to cross when routines wobble.

Behavioral therapies have a real evidence base. Cognitive behavioral therapy, which teaches structured ways of responding to stress and pain, and relaxation training or biofeedback, which teaches control over physical stress responses, are described by the Mayo Clinic as options that may help reduce migraine frequency. They are particularly relevant when stress is a consistent trigger or when medication options are limited, such as in pregnancy.

Neuromodulation devices, meaning small external devices that deliver electrical or magnetic stimulation to nerves involved in migraine, are approved for some people and may be used acutely or preventively. Evidence is still developing, and suitability is assessed individually.

Supplements deserve particular caution. Some, such as certain B vitamins and minerals, have modest supporting evidence and are mentioned by the Mayo Clinic as possibilities to discuss; others are widely promoted with little support. None should be started without telling the prescriber, because interactions with preventives are possible and because a supplement is not automatically safe in pregnancy.

The realistic role of these measures is as foundation, not replacement. Someone with fifteen migraine days a month is unlikely to reach a comfortable frequency through sleep hygiene alone, but the same person is likely to get more from a preventive when the foundation is in place.

What people often get wrong about acute and preventive migraine treatment

Some misunderstandings surface so often in clinic that they are worth addressing directly.

A preventive should stop the headache I have today. It will not, and judging it that way leads people to stop a medicine that is quietly working. Prevention is measured in monthly counts, not afternoons.

If I still get migraines, the preventive has failed. A meaningful response is commonly defined as roughly halving migraine days, per the Cleveland Clinic. Going from twelve days to six is a genuine success even though six attacks remain.

Waiting to take rescue medicine proves I am not dependent on it. Guidance consistently favors early use during an attack. What creates problems is frequency across the month, not promptness within an attack.

Over-the-counter pain relievers are safe to take daily. They are among the most common causes of medication overuse headache when taken on many days a month.

There is a 5-4-3-2-1 rule for migraine. No such rule exists in migraine guidelines. The phrase describes a grounding exercise for anxiety, in which a person names five things they can see, four they can touch, and so on. It may help someone stay calm during an attack, but it is not a treatment framework and does not appear in any major headache guidance.

The 5 C’s are the official migraine trigger list. This is a popular mnemonic, usually listing chocolate, cheese, citrus, caffeine and cured meats. Trigger evidence is far more individual than any list implies; the NHS notes that triggers vary widely and that keeping a diary is more reliable than avoiding foods on a generic list. Cutting out foods that never affected you adds burden without benefit.

Newer always means safer. Newer means less long-term data. It may also mean a better fit for people who cannot take older drugs, which is different.

Each of these errors pushes people toward either overusing the fast drawer or abandoning the slow one, which is why they matter beyond trivia.

Questions to ask your care team about your migraine plan

A good consultation about migraine treatment is a two-way exchange, and the right questions can turn a rushed appointment into a plan you understand. Bring your headache diary, a list of everything you take including supplements, and the answers to these.

• For each medicine I have, is it for the attack, for the background, or both, and how should I use it in each role?
• How many days a month can I safely use my rescue medicine, and what should I do if I find myself needing it more often than that?
• How long should I stay on this preventive before we judge whether it is helping, and what would count as success for me?
• What side effects are most likely with this class, which ones usually settle, and which ones should prompt me to contact you before the next review?
• Are there reasons in my history, such as heart risk, blood pressure or pregnancy plans, that rule certain classes in or out for me?
• If this preventive does not work, what would we try next, and how many options are realistically available before we consider referral?
• Which non-drug measures are most relevant to my pattern, and are any supplements I am considering safe alongside this plan?
• What is the plan for eventually reducing or stopping the preventive if things go well, and how would that be done?
• Which symptoms, if they appeared during an attack, would mean I should seek urgent care rather than wait it out?

Write the answers down or ask for them in the after-visit summary. A plan that lives only in memory tends to collapse into the two most common errors described earlier. A plan that is written, with each medicine’s role and monthly limit stated plainly, is one you can follow on a bad day when thinking clearly is hardest.

If anything in this article contradicts what your clinician has told you, their advice takes precedence. They know your history; a magazine does not.

When to call your doctor: red flags and when a migraine is not just a migraine

Most migraine attacks, however miserable, are not dangerous. A small number of headaches signal something else, and both the Mayo Clinic and MedlinePlus list features that should prompt emergency care rather than a wait for the usual medicine to work.

Seek emergency help if a headache is sudden and severe, reaching its worst within seconds to a minute, sometimes described as a thunderclap; if it comes with fever, stiff neck, confusion, seizures, double vision, weakness, numbness or trouble speaking; if it follows a head injury; if it is a new kind of headache in someone over 50; or if a chronic headache pattern suddenly changes character or becomes progressively worse. Weakness or numbness on one side, slurred speech or facial drooping should be treated as a possible stroke even in someone with a long migraine history, because migraine aura and stroke can look alike and only assessment can tell them apart.

Contact your treating team promptly, though not necessarily as an emergency, if an attack lasts beyond 72 hours without relief, since the NINDS notes this exceeds the typical range and may need different treatment; if you are using rescue medicine on 10 or more days a month; if a new preventive is causing side effects you cannot tolerate; if you develop chest pain or tightness after taking a triptan; if you become pregnant or plan to while on a preventive; or if attacks are becoming more frequent despite treatment.

Do not stop a preventive abruptly on your own. Several classes cause rebound effects or withdrawal symptoms when stopped suddenly, and the safe approach is a supervised reduction. Equally, do not increase or add rescue medicine to cover a failing plan; that is the road to overuse headache, and the better step is a conversation about adjusting prevention.

The decision about what to change, and when, belongs with the clinicians who know your history. This section exists so you know when that conversation cannot wait.

Frequently asked questions

What is the difference between acute and preventive migraine treatment?

Acute treatment is taken when an attack starts and aims to stop pain and nausea within hours, while preventive treatment is taken on a regular schedule to reduce how often and how severely attacks occur over months. Most people with frequent migraine use both, and the right combination is decided with a treating clinician based on attack frequency, disability and other health conditions.

When to start migraine prevention?

Prevention is usually discussed when migraine occurs on four or more days a month, when attacks are severe or long-lasting, when rescue medicines fail or cause side effects, or when acute medicine is being used often enough to risk overuse headache. People with infrequent attacks that respond to early acute treatment are often asked to wait. The decision rests with the prescribing clinician after reviewing a headache diary.

How do triptans work for migraine?

Triptans act on serotonin receptors to narrow swollen blood vessels around the brain and quiet pain signaling in the trigeminal nerve, the main sensory nerve of the head. They are taken at the start of an attack, not preventively. Because they constrict vessels, they are generally avoided in people at risk of heart attack or stroke, and frequent use can lead to medication overuse headache.

What is medication overuse headache?

Medication overuse headache is a near-daily headache that develops when acute pain medicines are taken too frequently, typically on 10 or more days a month for triptans, ergots, opioids or combination products, or 15 or more for simple pain relievers, over several months. Treatment usually involves a supervised reduction in the overused medicine, often paired with starting or adjusting a preventive, under a clinician’s guidance.

What are the main migraine preventive medication options?

Mainstream options include certain blood pressure medicines such as beta blockers, some antiseizure medicines, certain tricyclic antidepressants, CGRP monoclonal antibodies given by injection, some oral gepants taken on a schedule, and botulinum toxin for chronic migraine. No single class is best for everyone; the choice depends on coexisting conditions, side effect profiles, pregnancy plans and personal priorities, and is made by the prescriber.

Are gepants safer than triptans?

Neither class is universally safer. Gepants block the CGRP receptor without narrowing blood vessels, which makes them an option for people with heart or stroke risk who cannot take triptans. Triptans, however, have decades of safety data, while gepants are newer and long-term evidence is still accumulating. The safer choice depends on the individual’s cardiovascular history and is a decision for the prescribing clinician.

What is the most effective preventive treatment for migraines?

There is no single most effective preventive. Across established classes, trial results fall in a broadly similar range, and a meaningful response is commonly defined as roughly halving migraine days. Individual response varies widely, so clinicians choose based on fit: coexisting conditions, side effects, pregnancy plans and prior responses. Trying a second or third class when the first disappoints is common and expected.

How long does it take for preventive migraine medication to work?

Preventives typically need several weeks to a few months of consistent use before their effect on attack frequency becomes clear, according to the Mayo Clinic. Side effects often appear before benefits do. Clinicians usually review a headache diary after a fair trial before deciding whether to continue, adjust or switch, and no preventive should be stopped abruptly without medical advice.

What is the 5 4 3 2 1 rule for migraines?

There is no 5-4-3-2-1 rule in migraine guidelines. The phrase refers to a grounding technique for anxiety in which a person names five things they can see, four they can touch, three they can hear, two they can smell and one they can taste. It may help someone stay calm during an attack, but it is not a migraine treatment and does not replace acute or preventive medicine.

What are the 5 C's for migraines?

The 5 C’s is a popular mnemonic for supposed food triggers, usually chocolate, cheese, citrus, caffeine and cured meats. It is not an official clinical list. Trigger evidence is highly individual, and the NHS advises keeping a diary to identify personal triggers rather than avoiding foods on a generic list. Eliminating foods that have never affected you adds burden without benefit.

References

• Migraine Headaches (Cleveland Clinic)
• Migraine (NHS)
• Migraine (National Institute of Neurological Disorders and Stroke, NIH)
• Migraine (MedlinePlus)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.